Case report shows partial response in advanced myxoid pleomorphic liposarcoma after treatment with Eribulin and sintilimab, indicating a novel approach.
Myxoid pleomorphic liposarcoma (MPLPS) is an ultra-rare subtype of soft tissue sarcoma. The limited number of reported cases has led to significant challenges in its clinical management. Here, we present the case of a 52-year-old woman diagnosed with advanced retroperitoneal MPLPS. As first-line therapy, she underwent 4 cycles of chemotherapy with doxorubicin and ifosfamide. Anlotinib was subsequently added to the first-line regimen. Following this, she received gemcitabine plus albumin paclitaxel as second-line therapy. Notably, a partial response (PR) was achieved and sustained for 12 months following the administration of eribulin and sintilimab combined with radiotherapy. The demonstrated effectiveness of this multidisciplinary approach underscores its potential as a novel treatment strategy for patients with advanced MPLPS. To our knowledge, this article represents the first detailed documentation of multidisciplinary diagnosis and treatment of MPLPS.
No takes yet. Share an insight, caveat, or question.
Zhuo et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: